# Heartflow, Inc.: overview HTFL · Nasdaq · CIK 1464521 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/htfl.md) · [Financials](/companies/htfl/financials.md) · [Filings](/companies/htfl/filings.md) · [Insiders](/companies/htfl/insiders.md) Latest reported revenue: [$64.1m](/filings/0001464521-26-000131.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001464521-26-000131). ## Last eight quarters | Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [32.9](/filings/0001464521-25-000019.md) | [35.0 d](/filings/0001464521-26-000042.md) | [37.2](/filings/0001464521-26-000071.md) | [43.4](/filings/0001464521-26-000131.md) | [46.3](/filings/0001464521-25-000019.md) | [49.1 d](/filings/0001464521-26-000042.md) | [52.6](/filings/0001464521-26-000071.md) | [64.1](/filings/0001464521-26-000131.md) | | Gross margin | % | [75.7%](/filings/0001464521-25-000019.md) | [75.0% d](/filings/0001464521-26-000042.md) | [75.1%](/filings/0001464521-26-000071.md) | [75.5%](/filings/0001464521-26-000131.md) | [76.5%](/filings/0001464521-25-000019.md) | [79.5% d](/filings/0001464521-26-000042.md) | [80.2%](/filings/0001464521-26-000071.md) | [83.0%](/filings/0001464521-26-000131.md) | | Operating margin | % | [(45.3%)](/filings/0001464521-25-000019.md) | [(45.9%) d](/filings/0001464521-26-000042.md) | [(47.0%)](/filings/0001464521-26-000071.md) | [(31.6%)](/filings/0001464521-26-000131.md) | [(32.6%)](/filings/0001464521-25-000019.md) | [(36.1%) d](/filings/0001464521-26-000042.md) | [(56.1%)](/filings/0001464521-26-000071.md) | [(27.9%)](/filings/0001464521-26-000131.md) | | Net margin | % | [(58.1%)](/filings/0001464521-25-000019.md) | [(94.3%) d](/filings/0001464521-26-000042.md) | [(86.9%)](/filings/0001464521-26-000131.md) | [(21.2%)](/filings/0001464521-26-000131.md) | [(109.9%)](/filings/0001464521-25-000019.md) | [(49.7%) d](/filings/0001464521-26-000042.md) | [(52.1%)](/filings/0001464521-26-000131.md) | [(24.6%)](/filings/0001464521-26-000131.md) | | Diluted EPS | $ per share | [(3.43)](/filings/0001464521-25-000019.md) | not reported | [(5.25)](/filings/0001464521-26-000071.md) | [(1.46)](/filings/0001464521-26-000131.md) | [(1.04)](/filings/0001464521-25-000019.md) | not reported | [(0.32)](/filings/0001464521-26-000071.md) | [(0.18)](/filings/0001464521-26-000131.md) | | Free cash flow | $m | [(11.3) d](/filings/0001464521-25-000019.md) | [(14.4) d](/filings/0001464521-26-000042.md) | [(14.3)](/filings/0001464521-26-000071.md) | [(28.1) d](/filings/0001464521-26-000131.md) | [(4.2) d](/filings/0001464521-25-000019.md) | [(12.5) d](/filings/0001464521-26-000042.md) | [(32.0)](/filings/0001464521-26-000071.md) | [(10.5) d](/filings/0001464521-26-000131.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2023-12-31) | FY (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $m | [87.2](/filings/0001464521-26-000042.md) | [126](/filings/0001464521-26-000042.md) | [176](/filings/0001464521-26-000042.md) | | Gross margin | % | [66.6%](/filings/0001464521-26-000042.md) | [75.1%](/filings/0001464521-26-000042.md) | [76.8%](/filings/0001464521-26-000042.md) | | Operating margin | % | [(83.6%)](/filings/0001464521-26-000042.md) | [(48.7%)](/filings/0001464521-26-000042.md) | [(36.4%)](/filings/0001464521-26-000042.md) | | Net margin | % | [(109.7%)](/filings/0001464521-26-000042.md) | [(76.6%)](/filings/0001464521-26-000042.md) | [(66.3%)](/filings/0001464521-26-000042.md) | | Diluted EPS | $ per share | [(25.32)](/filings/0001464521-26-000042.md) | [(17.98)](/filings/0001464521-26-000042.md) | [(3.17)](/filings/0001464521-26-000042.md) | | Free cash flow | $m | [(82.5)](/filings/0001464521-26-000042.md) | [(73.4)](/filings/0001464521-26-000042.md) | [(59.0)](/filings/0001464521-26-000042.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/htfl/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2026-10-22 | [Rogers Campbell](/insiders/1585724.md) | Chief Medical Officer, Officer | Sale (S) | 23,933 | $55.01 | $1.3m | [Form 4](/filings/0001464521-26-000156.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Bain Capital Life Sciences Investors, LLC](/funds/1703031.md) | 2026-06-30 | $247.9m | 8,448,158 | | Reduced −2,000,000 | | [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $230.7m | 7,864,226 | | Reduced −4,118,057 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $152.5m | 5,197,747 | | Added +3,735,163 | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $141.4m | 4,820,944 | | Reduced −576,858 | | [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $105.2m | 3,584,428 | | Added +1,538,490 | | [BAMCO INC /NY/](/funds/1017918.md) | 2026-06-30 | $94.6m | 3,225,133 | | Reduced −602,398 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $80.8m | 2,753,206 | | Added +859,711 | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $71.0m | 2,419,336 | | Not compared | | [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $67.4m | 2,298,718 | | Added +385,628 | | [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $53.1m | 2,180,976 | | Not compared | ## Recent filings [All 193 filings](/companies/htfl/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-13 | 16:11 ET | [10-Q](/filings/0001464521-26-000131.md) | Quarterly report, period 2026-06-30 | 0001464521-26-000131 | | 2026-08-13 | 16:02 ET | [8-K](/filings/0001464521-26-000129.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001464521-26-000129 | | 2026-06-18 | 16:10 ET | [8-K](/filings/0001464521-26-000081.md) | 5.07 Shareholder vote results | 0001464521-26-000081 | | 2026-05-14 | 16:31 ET | [10-Q](/filings/0001464521-26-000071.md) | Quarterly report, period 2026-03-31 | 0001464521-26-000071 | | 2026-05-14 | 16:03 ET | [8-K](/filings/0001464521-26-000069.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001464521-26-000069 | | 2026-04-29 | 09:00 ET | [DEF 14A](/filings/0001193125-26-189307.md) | Proxy statement, period 2026-06-16 | 0001193125-26-189307 | | 2026-03-18 | 16:17 ET | [10-K](/filings/0001464521-26-000042.md) | Annual report, period 2025-12-31 | 0001464521-26-000042 | | 2026-03-18 | 16:02 ET | [8-K](/filings/0001464521-26-000040.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001464521-26-000040 | | 2026-01-12 | 08:30 ET | [8-K](/filings/0001464521-26-000005.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001464521-26-000005 | | 2025-11-12 | 17:20 ET | [10-Q](/filings/0001464521-25-000019.md) | Quarterly report, period 2025-09-30 | 0001464521-25-000019 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001464521-26-000042.md), filed Mar 18, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/bce9cacc-28b0-4bf0-9371-cda36f8480fa) ## About the filer - CIK: 1464521 - Tickers: HTFL - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 18:01 ET. No prices; not investment advice.